Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
77 hedge funds and large institutions have $366M invested in Chinook Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 26 reducing their positions, and 8 closing their positions.
12% more capital invested
Capital invested by funds: $328M → $366M (+$38.4M)
0% more funds holding
Funds holding: 77 → 77 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
38% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 26
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.04M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.45M |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
+$772K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$584K |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$548K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$4.33M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$3.17M |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$2.56M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.63M |
| 5 |
Renaissance Technologies
New York
|
-$1.54M |
KDNY Hedge Fund Activity: Q1 2021 in Review
77 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2021, worth a combined $366M — up 12% from $328M a quarter earlier.
Fund positioning in KDNY was balanced in Q1 2021: 8 funds opened new positions, 8 closed out, 16 added to existing stakes and 26 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.04M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $4.33M sold.
- 77 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $366M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2021, up 12% quarter-over-quarter.
- 8 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of 0 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2021 was Millennium Management, an estimated $5.04M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2021 was Monashee Investment Management, an estimated $4.33M sold.
Based on aggregated 13F filings for Q1 2021.